Transforming growth factor β is increased in plasma of patients with hematologic malignancies after transfusion of platelet concentrates
Transforming growth factor β is increased in plasma of patients with hematologic malignancies after transfusion of platelet concentrates
复制标题
DOI：
10.1046/j.1537-2995.1998.38298193097.x
复制
发表时间：
1998-02-01
期刊：
影响因子：
2.9
通讯作者：
Böck, M
中科院分区：
文献类型：
--
作者：
Kunz, D;Luley, C;Böck, M
背景：转化生长因子β（1）（TGF-β（1））是一种有效的骨髓增殖抑制剂。研究设计和方法：在5天的储存期内，比较了通过单采术或血沉棕黄层法制备的血小板浓缩物血浆中TGF-β 1的水平。此外，恶性血液病患者输血前后的血浆TGF-β 1水平进行了监测。结果：血小板浓缩物上清液中的TGF-β 1水平比健康志愿者的血浆高55倍。在储存期间，观察到额外增加。因此，输注浓缩血小板导致恶性血液病患者血浆TGF-β 1水平显著升高（输血前：2.2 +/- 0.5 ng/mL;输血后：2.9 +/- 0.6 ng/mL），并且这些较高水平持续至少4小时。由于TGF-β 1降低造血祖细胞的克隆形成能力，因此认为血小板输注具有骨髓抑制作用。
BACKGROUND: Transforming growth factor beta(1) (TGF-beta(1)) acts as a potent inhibitor of bone marrow proliferation. High concentrations were found in human platelets, which release this cytokine during storage.STUDY DESIGN AND METHODS: TGF-beta(1) levels during a storage period of 5 days were compared in the plasma of platelet concentrates prepared by apheresis or by the buffy coat method. In addition, TGF-beta(1) plasma levels were monitored in patients with hematologic malignancies before and after transfusion.RESULTS: TGF-beta(1) levels in the supernatant of platelet concentrates were found to be 55 times higher than those in the plasma of healthy volunteer donors. During storage, an additional increase was observed. Accordingly, the transfusion of platelet concentrates resulted in a significant increase of plasma TGF-beta(1) levels in patients with hematologic malignancies (before transfusion: 2.2 +/- 0.5 ng/mL; after transfusion: 2.9 +/- 0.6 ng/mL), and these higher levels persisted for at least 4 hours.CONCLUSION: Because TGF-beta(1) reduces the clonogenic capacity of hematopoetic progenitor cells, a myelosuppressive effect of platelet transfusions is suggested.